Pharming Group N.V.
PHARHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Pharming Group N.V. (PHAR) is listed under Biotechnology. With a market capitalization of $813.9M, it sits in small-cap territory. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Market Cap
$813.9M
Beta
0.07
P/E (TTM)
82.14
P/E (Fwd)
37.46
EPS (TTM)
$0.14
EPS (Fwd)
$0.31
ROE
3.6%
ROA
3.5%
Cash
$158.3M
Total Debt
$113.3M
Free CF
$37.7M
52W Change
-16.9%
Annual Financials
Cash vs Debt
Where PHAR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PHAR finished 21.90% below its 150-day moving average ($14.34) and 25.97% below its 200-day moving average ($15.13). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PHAR overbought or oversold?
At the September 3, 2026 close, PHAR's RSI(14) was 31.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $158.3M in cash and $113.3M in debt, PHAR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $37.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 3.6% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $205.6M (2022) to $376.1M (2025), reflecting a 83% increase over the period.
The relatively low beta of 0.07 suggests PHAR is a less volatile holding compared to the broader index. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Pharming Group N.V.'s trajectory.